Article
A comparison of two phase I trial designs
Abstract
Phase I cancer chemotherapy trials are designed to determine rapidly the maximum tolerated dose of a new agent for further study. A recently proposed Bayesian method, the continual reassessment method, has been suggested to offer an improvement over the standard design of such trials. We find the previous comparisons did not completely address the relative performance of the designs as they would be used in practice. Our results indicate that with the continual reassessment method, more patients will be treated at very high doses and the trials will take longer to complete. We offer some suggested improvements to both the standard design and the Bayesian method.
Citing Literature
Number of times cited according to CrossRef: 216
- Cornelis M. van Tilburg, Ruth Witt, Melanie Heiss, Kristian W. Pajtler, Christoph Plass, Isabel Poschke, Michael Platten, Inga Harting, Oliver Sedlaczek, Angelika Freitag, David Meyrath, Lenka Taylor, Gnana Prakash Balasubramanian, Natalie Jäger, Elke Pfaff, Barbara C. Jones, Till Milde, Stefan M. Pfister, David T. W. Jones, Annette Kopp-Schneider, Olaf Witt, INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies, BMC Cancer, 10.1186/s12885-020-07008-8, 20, 1, (2020).
- Jun Yin, Ying Yuan, Checkerboard: a Bayesian efficacy and toxicity interval design for phase I/II dose-finding trials, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2020.1815033, (1-20), (2020).
- Yaqian Zhu, Wei-Ting Hwang, Yimei Li, Evaluating the effects of design parameters on the performances of phase I trial designs, Contemporary Clinical Trials Communications, 10.1016/j.conctc.2019.100379, (100379), (2019).
- Takashi Daimon, Akihiro Hirakawa, Shigeyuki Matsui, Takashi Daimon, Akihiro Hirakawa, Shigeyuki Matsui, Rule-Based Designs Considering Toxicity Alone, Dose-Finding Designs for Early-Phase Cancer Clinical Trials, 10.1007/978-4-431-55585-8_2, (9-32), (2019).
- Takashi Daimon, Akihiro Hirakawa, Shigeyuki Matsui, Takashi Daimon, Akihiro Hirakawa, Shigeyuki Matsui, Model-Based Designs Considering Toxicity Alone, Dose-Finding Designs for Early-Phase Cancer Clinical Trials, 10.1007/978-4-431-55585-8_3, (33-79), (2019).
- Lingyun Ji, Juan Pablo Lewinger, Mark Krailo, Susan Groshen, David V. Conti, Shahab Asgharzadeh, Richard Sposto, Improvements to the Escalation with Overdose Control design and a comparison with the restricted Continual Reassessment Method, Pharmaceutical Statistics, 10.1002/pst.1955, 18, 6, (659-670), (2019).
- Graham M. Wheeler, Adrian P. Mander, Alun Bedding, Kristian Brock, Victoria Cornelius, Andrew P. Grieve, Thomas Jaki, Sharon B. Love, Lang’o Odondi, Christopher J. Weir, Christina Yap, Simon J. Bond, How to design a dose-finding study using the continual reassessment method, BMC Medical Research Methodology, 10.1186/s12874-018-0638-z, 19, 1, (2019).
- Mei-Yin C. Polley, Ying Kuen Cheung, Early-Phase Platform Trials: A New Paradigm for Dose Finding and Treatment Screening in the Era of Precision Oncology, JCO Precision Oncology, 10.1200/PO.19.00057, 3, (1-8), (2019).
- Minghan Shi, Malathi Anantha, Mohamed Wehbe, Marcel B. Bally, David Fortin, Laurent-Olivier Roy, Gabriel Charest, Maxime Richer, Benoit Paquette, Léon Sanche, Liposomal formulations of carboplatin injected by convection-enhanced delivery increases the median survival time of F98 glioma bearing rats, Journal of Nanobiotechnology, 10.1186/s12951-018-0404-8, 16, 1, (2018).
- David Machin, Michael J. Campbell, Say Beng Tan, Sze Huey Tan, Genomic Targets and Dose‐Finding, Sample Sizes for Clinical, Laboratory and Epidemiology Studies, 10.1002/9781118874905, (239-250), (2018).
- David Machin, Michael J. Campbell, Say Beng Tan, Sze Huey Tan, Cumulative References, Sample Sizes for Clinical, Laboratory and Epidemiology Studies, 10.1002/9781118874905, (363-380), (2018).
- Ali A. Mokdad, Xian‐Jin Xie, Hong Zhu, David E. Gerber, Daniel F. Heitjan, Statistical justification of expansion cohorts in phase 1 cancer trials, Cancer, 10.1002/cncr.31577, 124, 16, (3339-3345), (2018).
- Dan E. Ganz, Briana Sexton-Stallone, Emily L. Brackett, Neil S. Forbes, Tissue transport affects how treatment scheduling increases the efficacy of chemotherapeutic drugs, Journal of Theoretical Biology, 10.1016/j.jtbi.2017.10.022, 438, (21-33), (2018).
- Donglin Yan, Nolan A. Wages, Emily V. Dressler, Improved adaptive randomization strategies for a seamless Phase I/II dose-finding design, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2018.1535496, (1-15), (2018).
- Efehan Ulas, Filiz Karaman, Tuba Koc, Impact of different model structure and prior distribution in continual reassessment method, Communications in Statistics - Simulation and Computation, 10.1080/03610918.2018.1476698, (1-15), (2018).
- Sharon B Love, Sarah Brown, Christopher J Weir, Chris Harbron, Christina Yap, Birgit Gaschler-Markefski, James Matcham, Louise Caffrey, Christopher McKevitt, Sally Clive, Charlie Craddock, James Spicer, Victoria Cornelius, Embracing model-based designs for dose-finding trials, British Journal of Cancer, 10.1038/bjc.2017.186, 117, 3, (332-339), (2017).
- P. S. Boonstra, T. M. Braun, J. M. G. Taylor, K. M. Kidwell, E. L. Bellile, S. Daignault, L. Zhao, K. A. Griffith, T. S. Lawrence, G. P. Kalemkerian, M. J. Schipper, Statistical controversies in clinical research: building the bridge to phase II—efficacy estimation in dose-expansion cohorts, Annals of Oncology, 10.1093/annonc/mdx045, 28, 7, (1427-1435), (2017).
- Brenda Gaydos, Michael Krams, Inna Perevozskaya, Frank Bred, Qing Liu, Paul Gallo, Don Berry, Christy Chuang-Stein, José Pinheiro, Alun Bedding, Adaptive Dose-Response Studies, Drug Information Journal, 10.1177/216847900604000411, 40, 4, (451-461), (2017).
- Alexina J. Mason, Juan Gonzalez‐Maffe, Killian Quinn, Nicki Doyle, Ken Legg, Peter Norsworthy, Roy Trevelion, Alan Winston, Deborah Ashby, Developing a Bayesian adaptive design for a phase I clinical trial: a case study for a novel HIV treatment, Statistics in Medicine, 10.1002/sim.7169, 36, 5, (754-771), (2016).
- Juan R. Cabrera, Jennie W. Taylor, Annette M. Molinaro, Phase I cancer clinical trials†, Neuro-Oncology Practice, 10.1093/nop/npw014, 4, 1, (67-72), (2016).
- Andrew P. Grieve, Response‐adaptive clinical trials: case studies in the medical literature, Pharmaceutical Statistics, 10.1002/pst.1778, 16, 1, (64-86), (2016).
- M. Iftakhar Alam, A comparison between the continual reassessment method and D-optimum design for dose finding in phase I clinical trials, Biometrical Letters, 10.1515/bile-2016-0006, 53, 2, (69-82), (2016).
- Minghan Shi, David Fortin, Benoit Paquette, Léon Sanche, Convection-enhancement delivery of liposomal formulation of oxaliplatin shows less toxicity than oxaliplatin yet maintains a similar median survival time in F98 glioma-bearing rat model, Investigational New Drugs, 10.1007/s10637-016-0340-0, 34, 3, (269-276), (2016).
- Marie-Karelle Riviere, Jacques-Henri Jourdan, Sarah Zohar, dfcomb: An R-package for phase I/II trials of drug combinations, Computer Methods and Programs in Biomedicine, 10.1016/j.cmpb.2015.10.018, 125, (117-133), (2016).
- Shubham Pant, Suzanne F. Jones, Carla D. Kurkjian, Jeffrey R. Infante, Kathleen N. Moore, Howard A. Burris, Donald S. McMeekin, Karim A. Benhadji, Bharvin K.R. Patel, Martin J. Frenzel, Jonathan D. Kursar, Maciej J. Zamek-Gliszczynski, Eunice S.M. Yuen, Edward M. Chan, Johanna C. Bendell, A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer, European Journal of Cancer, 10.1016/j.ejca.2015.11.021, 56, (1-9), (2016).
- Axel‐R. Hanauske, Daniel D. Hoff, Preclinical and Early Clinical Development of Chemotherapeutic Drugs, Mechanism‐Based Agents and Biologics, Holland‐Frei Cancer Medicine, 10.1002/9781119000822, (1-34), (2016).
- Satoshi Morita, Masakazu Toi, Shigehira Saji, Hiroji Iwata, Shinji Ohno, Yoshinori Ito, Tadashi Kobayashi, Yasuo Hozumi, Junichi Sakamoto, Practical Application of the Continual Reassessment Method to a Phase I Dose-Finding Trial in Advanced Breast Cancer, Drug Information Journal, 10.1177/009286150704100601, 41, 6, (691-700), (2016).
- Elizabeth Garrett-Mayer, The continual reassessment method for dose-finding studies: a tutorial, Clinical Trials: Journal of the Society for Clinical Trials, 10.1191/1740774506cn134oa, 3, 1, (57-71), (2016).
- Yinghui Zhou, Choosing the Number of Doses and the Cohort Size for Phase 1 Dose-Escalation Studies, Drug Information Journal, 10.1177/009286150503900203, 39, 2, (125-137), (2016).
- Yinghui Zhou, John Whitehead, Practical Implementation of Bayesian Dose-Escalation Procedures, Drug Information Journal, 10.1177/009286150303700108, 37, 1, (45-59), (2016).
- Seung-Ho Kang, Chul W. Ahn, An Investigation of the Traditional Algorithm-Based Designs for Phase 1 Cancer Clinical Trials, Drug Information Journal, 10.1177/009286150203600415, 36, 4, (865-873), (2016).
- Georgene Schroeder, Jeff A. Sloan, Stephen Cha, Pamela Atherton, Cristine Allmer, Charles Erlichman, Phase 1 Oncology Clinical Trials for Related Subpopulations: The Power Walk Design, Drug Information Journal, 10.1177/009286150203600313, 36, 3, (581-593), (2016).
- Seung-Ho Kang, Chul Ahn, The Expected Toxicity Rate at the Maximum Tolerated Dose in the Standard Phase I Cancer Clinical Trial Design, Drug Information Journal, 10.1177/009286150103500416, 35, 4, (1189-1199), (2016).
- Kimberly T. Perry, From Mouse to Man: The Early Clinical Testings, Drug Information Journal, 10.1177/009286159703100313, 31, 3, (729-736), (2016).
- Cathie Spino, Jordan S. Jahnke, David T. Selewski, Susan Massengill, Jonathan Troost, Debbie S. Gipson, Changing the Paradigm for the Treatment and Development of New Therapies for FSGS, Frontiers in Pediatrics, 10.3389/fped.2016.00025, 4, (2016).
- Marie-Karelle Riviere, Ying Yuan, Jacques-Henri Jourdan, Frédéric Dubois, Sarah Zohar, Phase I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomization, Statistical Methods in Medical Research, 10.1177/0962280216631763, (096228021663176), (2016).
- Philip S. Boonstra, Jincheng Shen, Jeremy M.G. Taylor, Thomas M. Braun, Kent A. Griffith, Stephanie Daignault, Gregory P. Kalemkerian, Theodore S. Lawrence, Matthew J. Schipper, A Statistical Evaluation of Dose Expansion Cohorts in Phase I Clinical Trials, JNCI: Journal of the National Cancer Institute, 10.1093/jnci/dju429, 107, 3, (2015).
- Jürgen Hummel, Song Wang, John Kirkpatrick, Using simulation to optimize adaptive trial designs: applications in learning and confirmatory phase trials, Clinical Investigation, 10.4155/cli.15.14, 5, 4, (401-413), (2015).
- Minghan Shi, David Fortin, Léon Sanche, Benoit Paquette, Convection-enhancement delivery of platinum-based drugs and LipoplatinTM to optimize the concomitant effect with radiotherapy in F98 glioma rat model, Investigational New Drugs, 10.1007/s10637-015-0228-4, 33, 3, (555-563), (2015).
- Shinjo YADA, Chikuma HAMADA, Overview of Continual Reassessment Method for Estimating the Maximum Tolerated Dose in Phase I Oncology Trials , Rinsho yakuri/Japanese Journal of Clinical Pharmacology and TherapeuticsRinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics, 10.3999/jscpt.46.11, 46, 1, (11-19), (2015).
- Ick Hoon Jin, Lin Huo, Guosheng Yin, Ying Yuan, Phase I trial design for drug combinations with Bayesian model averaging, Pharmaceutical Statistics, 10.1002/pst.1668, 14, 2, (108-119), (2015).
- M.‐K. Riviere, F. Dubois, S. Zohar, Competing designs for drug combination in phase I dose‐finding clinical trials, Statistics in Medicine, 10.1002/sim.6094, 34, 1, (1-12), (2014).
- Eunah Jang, Dongjae Kim, Maximum Tolerated Dose Estimation with Dose De-Escalation Design in a Phase I Clinical Trials, Korean Journal of Applied Statistics, 10.5351/KJAS.2014.27.7.1115, 27, 7, (1115-1123), (2014).
- Byoungchan Kim, Dongjae Kim, Maximum Tolerated Dose Estimation by Stopping Rule and SM3 Design in a Phase I Clinical Trial, Korean Journal of Applied Statistics, 10.5351/KJAS.2014.27.1.013, 27, 1, (13-20), (2014).
- Maiying Kong, Shesh N. Rai, Roberto Bolli, Statistical Methods for Selecting Maximum Effective Dose and Evaluating Treatment Effect When Dose–Response is Monotonic, Statistics in Biopharmaceutical Research, 10.1080/19466315.2013.826596, 6, 1, (16-29), (2014).
- Aaron R. Hansen, Donna M. Graham, Gregory R. Pond, Lillian L. Siu, Phase 1 Trial Design: Is 3 + 3 the Best?, Cancer Control, 10.1177/107327481402100304, 21, 3, (200-208), (2014).
- Elad Sharon, Mei-Yin Polley, Michael B. Bernstein, Mansoor Ahmed, Immunotherapy and Radiation Therapy: Considerations for Successfully Combining Radiation into the Paradigm of Immuno-Oncology Drug Development, Radiation Research, 10.1667/RR13707.1, 182, 2, (252-257), (2014).
- Xavier Paoletti, Adélaide Doussau, Dose Finding Methods in Oncology: From the Maximum Tolerated Dose to the Recommended Phase II Dose, Developments in Statistical Evaluation of Clinical Trials, 10.1007/978-3-642-55345-5, (335-361), (2014).
- Lawrence V. Rubinstein, Richard S. Ungerleider, Cooperative Cancer Trials , Wiley StatsRef: Statistics Reference Online, 10.1002/9781118445112, (2014).
- Jen‐pei Liu, Shein‐chung Chow, Minimum Therapeutically Effective Dose, Wiley StatsRef: Statistics Reference Online, 10.1002/9781118445112, (2014).
- Anastasia Ivanova, Phase I Trials in Oncology, Wiley StatsRef: Statistics Reference Online, 10.1002/9781118445112, (2014).
- Ying Kuen (Ken) Cheung, Coherence in Phase I Clinical Trials, Wiley StatsRef: Statistics Reference Online, 10.1002/9781118445112, (2014).
- Chul Ahn, Seung‐Ho Kang, Yang Xie, Optimal Biological Dose for Molecularly‐Targeted Therapies, Wiley StatsRef: Statistics Reference Online, 10.1002/9781118445112, (2014).
- Chul Ahn, Seung‐Ho Kang, Yang Xie, Song Zhang, Optimal Biological Dose for Molecularly Targeted Therapies, Wiley StatsRef: Statistics Reference Online, 10.1002/9781118445112, (1-12), (2014).
- Weili He, Jun Liu, Algorithm‐Based Designs, Wiley StatsRef: Statistics Reference Online, 10.1002/9781118445112, (2014).
- Douglas M. Potter, Robust Two‐Stage Model‐Guided Designs for Phase I Clinical Studies, Wiley StatsRef: Statistics Reference Online, 10.1002/9781118445112, (2014).
- Sylvie Chevret, Phase I Trials including Phase I Cancer Trials, Wiley StatsRef: Statistics Reference Online, 10.1002/9781118445112, (2014).
- Anastasia Ivanova, Dose Escalation and Up‐and‐Down Designs, Wiley StatsRef: Statistics Reference Online, 10.1002/9781118445112, (2014).
- Ying‐Kuen K. Cheung, Coherence in Phase I Clinical Trials, Methods and Applications of Statistics in Clinical Trials, 10.1002/9781118596005, (230-239), (2014).
- Anastasia Ivanova, Assaf P. Oron, Up‐and‐Down and Escalation Designs, Methods and Applications of Statistics in Clinical Trials, 10.1002/9781118596005, (353-361), (2014).
- Weili He, Jun Liu, Algorithm‐Based Designs, Methods and Applications of Statistics in Clinical Trials, 10.1002/9781118596005, (40-52), (2014).
- Sylvie Chevret, Phase I Trials, Methods and Applications of Statistics in Clinical Trials, 10.1002/9781118596005, (682-691), (2014).
- Anastasia Ivanova, Phase I Trials in Oncology, Methods and Applications of Statistics in Clinical Trials, 10.1002/9781118596005, (719-724), (2014).
- Chul Ahn, Seung‐Ho Kang, Yang Xie, Optimal Biological Dose for Molecularly Targeted Therapies, Methods and Applications of Statistics in Clinical Trials, 10.1002/9781118596333, (496-505), (2014).
- Marie‐Karelle Riviere, Ying Yuan, Frédéric Dubois, Sarah Zohar, A Bayesian dose‐finding design for drug combination clinical trials based on the logistic model, Pharmaceutical Statistics, 10.1002/pst.1621, 13, 4, (247-257), (2014).
- Anastasia Ivanova, Gary L. Rosner, Olga Marchenko, Tom Parke, Inna Perevozskaya, Yanping Wang, Advances in Statistical Approaches to Oncology Drug Development, Therapeutic Innovation & Regulatory Science, 10.1177/2168479013501309, 48, 1, (81-89), (2013).
- Tomoyuki Kakizume, Satoshi Morita, A Continual Reassessment Method With Cohort Size Adaptation Based on Bayesian Posterior Probabilities in Phase I Dose-Finding Studies, Therapeutic Innovation & Regulatory Science, 10.1177/2168479013500970, 48, 2, (213-219), (2013).
- Suyu Liu, Chunyan Cai, Jing Ning, Up-and-down designs for phase I clinical trials, Contemporary Clinical Trials, 10.1016/j.cct.2013.07.002, 36, 1, (218-227), (2013).
- Jay Bartroff, Tze Leung Lai, Mei-Chiung Shih, Jay Bartroff, Tze Leung Lai, Mei-Chiung Shih, Confidence Intervals and p-Values, Sequential Experimentation in Clinical Trials, 10.1007/978-1-4614-6114-2_7, (153-186), (2013).
- Jay Bartroff, Tze Leung Lai, Mei-Chiung Shih, Jay Bartroff, Tze Leung Lai, Mei-Chiung Shih, Introduction, Sequential Experimentation in Clinical Trials, 10.1007/978-1-4614-6114-2_1, (1-10), (2013).
- Jay Bartroff, Tze Leung Lai, Mei-Chiung Shih, Jay Bartroff, Tze Leung Lai, Mei-Chiung Shih, Time-Sequential Design of Clinical Trials with Failure-Time Endpoints, Sequential Experimentation in Clinical Trials, 10.1007/978-1-4614-6114-2_6, (123-152), (2013).
- Jay Bartroff, Tze Leung Lai, Mei-Chiung Shih, Jay Bartroff, Tze Leung Lai, Mei-Chiung Shih, Group Sequential Design of Phase II and III Trials, Sequential Experimentation in Clinical Trials, 10.1007/978-1-4614-6114-2_4, (77-100), (2013).
- Jay Bartroff, Tze Leung Lai, Mei-Chiung Shih, Jay Bartroff, Tze Leung Lai, Mei-Chiung Shih, Nonlinear Regression, Experimental Design, and Phase I Clinical Trials, Sequential Experimentation in Clinical Trials, 10.1007/978-1-4614-6114-2_2, (11-35), (2013).
- Jay Bartroff, Tze Leung Lai, Mei-Chiung Shih, Jay Bartroff, Tze Leung Lai, Mei-Chiung Shih, Sequential Testing Theory and Stochastic Optimization Over Time, Sequential Experimentation in Clinical Trials, 10.1007/978-1-4614-6114-2_3, (37-75), (2013).
- Jay Bartroff, Tze Leung Lai, Mei-Chiung Shih, Jay Bartroff, Tze Leung Lai, Mei-Chiung Shih, Sequential Methods for Vaccine Safety Evaluation and Surveillance in Public Health, Sequential Experimentation in Clinical Trials, 10.1007/978-1-4614-6114-2_5, (101-122), (2013).
- Jay Bartroff, Tze Leung Lai, Mei-Chiung Shih, Jay Bartroff, Tze Leung Lai, Mei-Chiung Shih, Adaptive Design of Confirmatory Trials, Sequential Experimentation in Clinical Trials, 10.1007/978-1-4614-6114-2_8, (187-223), (2013).
- Yuan Ji, Sue-Jane Wang, Safety Concerns of the 3+3 Design: A Comparison to the mTPI Design, Topics in Applied Statistics, 10.1007/978-1-4614-7846-1_11, (125-135), (2013).
- Guosheng Yin, Shurong Zheng, Jiajing Xu, Fractional Dose-Finding Methods with Late-Onset Toxicity in Phase I Clinical Trials, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2013.789892, 23, 4, (856-870), (2013).
- Yuan Ji, Sue-Jane Wang, Modified Toxicity Probability Interval Design: A Safer and More Reliable Method Than the 3 + 3 Design for Practical Phase I Trials, Journal of Clinical Oncology, 10.1200/JCO.2012.45.7903, 31, 14, (1785-1791), (2013).
- Jin Zhang, Thomas M. Braun, Jeremy M.G. Taylor, Adaptive prior variance calibration in the Bayesian continual reassessment method, Statistics in Medicine, 10.1002/sim.5621, 32, 13, (2221-2234), (2012).
- Takashi Daimon, The Continual Reassessment Method (CRM) and Related Topics^|^mdash;A Review. Part II: Modified/Extended CRMs and Related Designs., Japanese Journal of Biometrics, 10.5691/jjb.33.31, 33, 1, (31-76), (2012).
- John O’Quigley, Alexia Iasonos, John Crowley, Antje Hoering, Dose-Finding Designs Based on the Continual Reassessment Method, Handbook of Statistics in Clinical Oncology, Third Edition, 10.1201/b11800, (21-52), (2012).
- Christoph Gerlinger, Harald Siedentop, Oke Gerke, Ilka Schellschmidt, Jan Endrikat, Optimal dose de-escalation trial designs for novel contraceptives in women, Computational Statistics & Data Analysis, 10.1016/j.csda.2011.08.005, 56, 5, (1061-1068), (2012).
- Barry Storer, John Crowley, Antje Hoering, Choosing a Phase I Design, Handbook of Statistics in Clinical Oncology, Third Edition, 10.1201/b11800, (3-20), (2012).
- Yu Rim Kim, Dongjae Kim, Maximum Tolerated Dose Estimation Applied Biased Coin Design in a Phase I Clinical Trial, Communications for Statistical Applications and Methods, 10.5351/CKSS.2012.19.6.877, 19, 6, (877-884), (2012).
- Na-Mi Lee, Dong-Jae Kim, Two-Stage Maximum Tolerated Dose Estimation by Stopping Rule in a Phase I Clinical Trial, Communications for Statistical Applications and Methods, 10.5351/CKSS.2012.19.1.057, 19, 1, (57-64), (2012).
- J.M. McGree, C.C. Drovandi, M.H. Thompson, J.A. Eccleston, S.B. Duffull, K. Mengersen, A.N. Pettitt, T. Goggin, Adaptive Bayesian compound designs for dose finding studies, Journal of Statistical Planning and Inference, 10.1016/j.jspi.2011.12.029, 142, 6, (1480-1492), (2012).
- Takashi Daimon, The Continual Reassessment Method (CRM) and Related Topics^|^mdash;A Review. Part I: Understanding the CRM for Dose-Finding Studies., Japanese Journal of Biometrics, 10.5691/jjb.33.1, 33, 1, (1-29), (2012).
- Zhengjia Chen, Yichuan Zhao, Ye Cui, Jeanne Kowalski, Methodology and Application of Adaptive and Sequential Approaches in Contemporary Clinical Trials, Journal of Probability and Statistics, 10.1155/2012/527351, 2012, (1-20), (2012).
- Ju Hee Park, Dongjae Kim, Adjusted maximum tolerated dose estimation by stopping rule in phaseⅠclinical trial, Journal of the Korean Data and Information Science Society, 10.7465/jkdi.2012.23.6.1085, 23, 6, (1085-1091), (2012).
- Mourad Tighiouart, Galen Cook-Wiens, André Rogatko, Escalation with Overdose Control Using Ordinal Toxicity Grades for Cancer Phase I Clinical Trials, Journal of Probability and Statistics, 10.1155/2012/317634, 2012, (1-18), (2012).
- Mourad Tighiouart, Galen Cook-Wiens, André Rogatko, Incorporating a Patient Dichotomous Characteristic in Cancer Phase I Clinical Trials Using Escalation with Overdose Control, Journal of Probability and Statistics, 10.1155/2012/567819, 2012, (1-10), (2012).
- Ying Kuen Cheung, Designs for Phase I Trials, Designs for Clinical Trials, 10.1007/978-1-4614-0140-7, (1-27), (2012).
- Shanhong Guan, Statistical Designs for Early Phases of Cancer Clinical Trials, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2011.571801, 22, 6, (1109-1126), (2012).
- Sarah Zohar, Vincent Levy, Dose Estimation, Pharmaceutical Medicine, 10.1007/BF03256680, 22, 1, (35-40), (2012).
- Masahiko Gosho, Kengo Nagashima, Yasunori Sato, Study Designs and Statistical Analyses for Biomarker Research, Sensors, 10.3390/s120708966, 12, 7, (8966-8986), (2012).
- Sarah Zohar, Matthieu Resche-Rigon, Sylvie Chevret, Using the continual reassessment method to estimate the minimum effective dose in phase II dose-finding studies: a case study, Clinical Trials: Journal of the Society for Clinical Trials, 10.1177/1740774511411593, 10, 3, (414-421), (2011).
- Ying Cheung, References, Dose Finding by the Continual Reassessment Method, 10.1201/b10783-19, (179-186), (2011).
- Joo-Hyoung Lee, Hae-Hiang Song, Continual Reassessment Method in Phase I Clinical Trials for Leukemia Patients, Communications for Statistical Applications and Methods, 10.5351/CKSS.2011.18.5.581, 18, 5, (581-594), (2011).
- Lili Zhao, Julia Lee, Rajen Mody, Thomas M Braun, The superiority of the time-to-event continual reassessment method to the rolling six design in pediatric oncology Phase I trials, Clinical Trials: Journal of the Society for Clinical Trials, 10.1177/1740774511407533, 8, 4, (361-369), (2011).
- See more
